vTv Therapeutics, Inc. Class A VTVT 深 沪
已收盘 05-22 16:00:00 美东时间
34.405
-1.095
-3.08%
华盛通- 最 高35.95
- 今 开35.30
- 成交量 6.06万股
- 最 低 33.92
- 昨 收 35.50
- 总市值 1.36亿
- 52周最高 44.00
- 市盈率 静 --
- 换手率 1.54%
- 52周最低 14.00
- 委 比 98.10%
- 总股本 393.89万
- 历史最高 560.00
- 量 比 1.28
- 振 幅 5.72%
- 历史最低 7.38
- 每 手 1
- 风险率 9.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多vTv Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
vTv Therapeutics shares are trading higher after the company reported better-th...
05-15 00:35
vTv Therapeutics Expands At-The-Market Share Program Capacity
vTv Therapeutics ( ($VTVT) ) has provided an update. On May 13, 2026, vTv Thera...
05-14 07:07
vTv Therapeutics Q1 EPS $1.65 Beats $(0.10) Estimate, Sales $36.839M Beat $20.000M Estimate
vTv Therapeutics (NASDAQ:VTVT) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $(0.10) by 1933.33 percent. This is a 314.29 percent increase over losses of $(0.77) per share
05-14 04:53
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 39,500 stock options to two non-executive employees, with a weighted average exercise price of $32.00 per share. The options vest over four years, with 25% vesting after one year and the remainder vesting quarterly over the next 36 months, subject to continued employment. The options have a 10-year term and are governed by the 2026 Inducement Plan. vTv is focused on developing cadisegliatin, a potential first-in-class ora...
05-08 20:15
vTv Therapeutics to Participate in Upcoming May Investor Conferences
vTv Therapeutics Inc. announced its participation in two investor conferences in May 2026: the H.C. Wainwright BioConnect Conference on May 19 and the Alliance Global Partners Healthcare Showcase on May 20. The company will discuss its lead drug candidate, cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes, currently in Phase 3 trials. Cadisegliatin has received Breakthrough Therapy designation from the FDA. Webcasts of th...
05-07 12:00
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed outlook on certain stocks. See analyst ratings and advice on Rush Street, Jabil, Enovix, Planet Fitness, and vTv Therapeutics.
03-12 20:16
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
BTIG Reiterates Buy on vTv Therapeutics, Maintains $49 Price Target
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $49 price target.
03-12 01:25
